B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Koff, Jean L.; Flowers, Christopher R.
• Is Part Of: Expert review of hematology. Volume 9:Issue 6(2016)
• Page Start: 553
• Page End: 561
• Publication Date: 2016-06-02
• Subjects: B cell -- lymphoma -- non-Hodgkin lymphoma -- diffuse large B cell lymphoma -- autoimmune disease -- systemic lupus erythematosus -- epidemiology; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2016.1180972
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Introduction : Diffuse large B cell lymphoma (DLBCL) is characterized by genetic, genomic and clinical heterogeneity. Autoimmune diseases (AIDs) have recently been shown to represent significant risk factors for development of DLBCL. Areas covered : Studies that examined the relationships between AIDs and lymphoma in terms of pathogenesis, genetic lesions, and treatment were identified in the MEDLINE database using combinations of medical subject heading (MeSH) terms. Co-authors independently performed study selection for inclusion based on appropriateness of the study question and nature of the study design and sample size. Expert commentary : Identification of AID as a substantial risk factor for DLBCL raises new questions regarding how autoimmunity influences lymphomagenesis and disease behavior. It will be important to identify whether DLBCL cases arising in the setting of AID harbor inferior prognoses, and, if so, whether they also exhibit certain molecular abnormalities that may be targeted to overcome such a gap in clinical outcomes.